PNR Ref
 PNR Req
 Blank PNRs
 Spotting
 Timeline
 Travel Tip
 Trip
 Race
 Social
 Greeting
 Poll
 Img
 PNR
 Pic
 Blog
 News
 Conf TL
 RF Club
 Convention
 Monitor
 Topic
 Bookmarks
 Rating
 Correct
 Wrong
 Stamp
 HJ
 Vote
 Pred
 @
 FM Alert
 FM Approval
 Pvt
News Super Search
 ↓ 
×
Member:
Posting Date From:
Posting Date To:
Category:
Zone:
Language:
IR Press Release:

Search
  Go  

Rockfort Express: திருச்சி அவனது கோட்டை, இரவில் சென்னை வரை வேட்டை, அவன் தான் மலைக்கோட்டை. - Vijay Baradwaj

Full Site Search
  Full Site Search  
 
Thu Nov 26 10:32:23 IST
Home
Trains
ΣChains
Atlas
PNR
Forum
Topics
Gallery
News
FAQ
Trips/Spottings
Login
Advanced Search
<<prev entry    next entry>>
News Entry# 422816
Oct 26 (21:53) Prepare for Oxford covid vaccine next month, UK hospital told: Report (www.livemint.com)
*covid-19
0 Followers
626 views

News Entry# 422816  Blog Entry# 4759428   
  Past Edits
This is a new feature showing past edits to this News Post.
Staff at a major London hospital trust have been told to be ready to receive the first batches of the vaccine being developed by the University of Oxford and AstraZeneca Plc, The Sun newspaper reported on Monday.

The Sun said the hospital was told to prepare for the vaccine from the "week commencing the 2 November."

The
...
more...
COVID-19 vaccine being developed by the University of Oxford and AstraZeneca Plc produces a robust immune response in elderly people, the Financial Times said on Monday, citing early results.

A vaccine that works is seen as a game-changer in the battle against the novel coronavirus, which has killed more than 1.15 million people, hammered the global economy and shuttered normal life across the world.

The Oxford vaccine triggers protective antibodies and T-cells in older age groups, the FT said, citing two people familiar with the finding.

Immunogenicity blood tests carried out on a subset of older participants echo data released in July which showed the vaccine generated "robust immune responses" in a group of healthy adults aged between 18 and 55, the newspaper reported.

Details of the finding are expected to be published shortly in a clinical journal, the FT said. It did not name the publication.

The FT cautioned that positive immunogenicity tests do not guarantee the vaccine will ultimately prove safe and effective in older people.

AstraZeneca, which is developing the vaccine with Oxford University researchers, is seen as a frontrunner in the race to produce a vaccine to protect against COVID-19.

OXFORD VACCINE

The vaccine is expected to be one of the first from big pharma to secure regulatory approval, along with Pfizer and BioNTech's candidate.

The vaccine is likely to provide protection for about a year, CEO Pascal Soriot said in June.

Called AZD1222 or ChAdOx1 nCoV-19, the vaccine was developed by Oxford University scientists and licensed to AstraZeneca in April, which took on the task of scaling trials and production.

The British drugmaker has signed several supply and manufacturing deals with companies and governments around the world as it gets closer to reporting early results of a late-stage clinical trial.

AstraZeneca resumed the U.S. trial of the experimental vaccine after approval by U.S. regulators, the company said on Friday.

Click here to read the Mint ePaperMint is now on Telegram. Join Mint channel in your Telegram and stay updated with the latest business news.

Wait for it…

Log in to our website to save your bookmarks. It'll just take a moment.

Your session has expired, please login again.

Congratulations!

You are now subscribed to our newsletters. In case you can’t find any email from our side, please check the spam folder.
Go to Full Mobile site